Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Moderate to Severe Ulcerative Colitis
Interventions
DRUG

Hemay005 tablets

Hemay005 tablets (15mg/tablet)will be orally administered twice daily.

DRUG

Hemay005 placebo tablets

Hemay005 placebo tablets will be orally administered twice daily.

Trial Locations (18)

Unknown

The Fourth Affiliated Hospital of Anhui Medical University, Hefei

The First Affiliated Hospital of Fujian Medical University, Fuzhou

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

First Affiliated Hospital of Zhengzhou University, Zhengzhou

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Xiangya Hospital of Central South University, Changsha

The First Affiliated Hospital of Nanchang University, Nanchang

Shengjing Hospital Affiliated to China Medical University, Shenyang

Qilu Hospital of Shandong University, Jinan

Shandong Provincial Hospital, Jinan

Sichuan Provincial People's Hospital, Chengdu

First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing

Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing

Peking University Third Hospital, Beijing

Chongqing People's Hospital, Chongqing

Shanghai Oriental Hospital, Shanghai

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Ganzhou Hemay Pharmaceutical Co., Ltd

INDUSTRY